Background Nirmatrelvir/ritonavir, the first severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) protease inhibitor, reduces the risk of hospitalization and death by …

Abstract Nirmatrelvir/ritonavir (NMV‐r) is an effective anti‐SARS‐CoV‐2 agent and has been
recommended in the treatment of nonhospitalized patients with COVID‐19. In rare …

We enrolled 7 individuals with recurrent symptoms or antigen test conversion following
nirmatrelvir-ritonavir treatment. High viral loads (median 6.1 log10 copies/mL) were detected …

In a cohort of 483 high-risk patients treated with nirmatrelvir/ritonavir for COVID-19, 2
patients (0.4%) required hospitalization by day 30. Four patients (0.8%) experienced …

Oral nirmatrelvir/ritonavir is approved as treatment for acute COVID‐19, but the effect of
treatment during acute infection on risk of Long COVID is unknown. We hypothesized that …

Abstract Background Nirmatrelvir/ritonavir (N/R) reduces severe outcomes from coronavirus
disease 2019 (COVID-19); however, rebound after treatment has been reported. We …

Background The oral protease inhibitor nirmatrelvir has shown substantial efficacy in high-
risk, unvaccinated patients infected with the B. 1.617. 2 (delta) variant of severe acute …

Background: Data are conflicting regarding an association between treatment of acute
COVID-19 with nirmatrelvir− ritonavir (NR) and virologic rebound (VR). Objective: To …

We isolated a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) BA. 2 variant
from a person with coronavirus disease 2019 recrudescence after nirmatrelvir/ritonavir …

Reports of symptomatic rebound and/or test re-positivity among COVID-19 patients following
the standard five-day treatment course of nirmatrelvir/ritonavir have sparked debates …